DDInter130 DDInter1180
Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize. Beta-blockers quickly became popular in clinical use and where subsequently investigated for use in myocardial infarction, arrhythmias, and hypertension during the 1960s. Later they continued to be investigated for use in heart failure throughout the 1970-1980s. Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.[label] Despite being one of the most widely prescribed beta blockers, evidence suggests atenolol may not significantly reduce mortality, and only modestly reduce the risk of cardiovascular disease in patients with hypertension.[A235850,A235855] A Cochrane review
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Atenolol {u} (Compound) resembles {v} (Compound) Oxprenolol
Atenolol {u} (Compound) resembles {v} (Compound) Chlorphenesin
Atenolol {u} (Compound) binds {v} (Gene) ADRB2
Atenolol {u} (Compound) upregulates {v} (Gene) UBQLN2
Atenolol {u} (Compound) causes {v} (Side Effect) Dry mouth
Atenolol (Compound) resembles Oxprenolol (Compound)
Atenolol (Compound) resembles Chlorphenesin (Compound)
Atenolol (Compound) binds ADRB2 (Gene)
Atenolol (Compound) upregulates UBQLN2 (Gene)
Atenolol (Compound) causes Dry mouth (Side Effect)